DK3129037T3 - Onkolytiske koppevirusvektorer - Google Patents
Onkolytiske koppevirusvektorer Download PDFInfo
- Publication number
- DK3129037T3 DK3129037T3 DK15720276.3T DK15720276T DK3129037T3 DK 3129037 T3 DK3129037 T3 DK 3129037T3 DK 15720276 T DK15720276 T DK 15720276T DK 3129037 T3 DK3129037 T3 DK 3129037T3
- Authority
- DK
- Denmark
- Prior art keywords
- oncolytic
- virus vectors
- smallpox virus
- smallpox
- vectors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/249,713 US9687515B2 (en) | 2007-11-19 | 2014-04-10 | Poxviral oncolytic vectors |
| PCT/EP2015/057654 WO2015155263A1 (en) | 2014-04-10 | 2015-04-09 | Poxviral oncolytic vectors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3129037T3 true DK3129037T3 (da) | 2020-02-03 |
Family
ID=53051793
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK15720276.3T DK3129037T3 (da) | 2014-04-10 | 2015-04-09 | Onkolytiske koppevirusvektorer |
Country Status (10)
| Country | Link |
|---|---|
| EP (1) | EP3129037B1 (enExample) |
| JP (1) | JP6657115B2 (enExample) |
| KR (1) | KR102457060B1 (enExample) |
| CN (1) | CN106413726B (enExample) |
| AU (1) | AU2015243297B2 (enExample) |
| CA (1) | CA2943871C (enExample) |
| DK (1) | DK3129037T3 (enExample) |
| ES (1) | ES2768715T3 (enExample) |
| IL (1) | IL247535B (enExample) |
| WO (1) | WO2015155263A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018091680A1 (en) * | 2016-11-18 | 2018-05-24 | Transgene Sa | Cowpox-based oncolytic vectors |
| EP3610870A4 (en) * | 2017-03-31 | 2020-12-09 | Ogata, Hisanobu | METHOD OF EXPANSION OF AN ONCOLYTIC VIRUS AND ANTI-TUMOR AGENT |
| IL284421B2 (en) * | 2018-12-28 | 2025-05-01 | Transgene | M2-defective poxvirus |
| CN110747174A (zh) * | 2019-10-30 | 2020-02-04 | 青岛宁逸生物科技有限公司 | 一种用于肿瘤治疗的重组病毒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5364773A (en) | 1991-03-07 | 1994-11-15 | Virogenetics Corporation | Genetically engineered vaccine strain |
| AU672359B2 (en) * | 1991-03-07 | 1996-10-03 | Virogenetics Corporation | Genetically engineered vaccine strain |
| US5358866A (en) | 1991-07-03 | 1994-10-25 | The United States Of America As Represented By The Department Of Health And Human Services | Cytosine deaminase negative selection system for gene transfer techniques and therapies |
| US5856153A (en) | 1994-11-17 | 1999-01-05 | Cayla | Suicide genes and new associations of pyrimidine nucleobase and nucleoside analogs with new suicide genes for gene therapy of acquired diseases |
| FR2777570A1 (fr) | 1998-04-17 | 1999-10-22 | Transgene Sa | Mutant ayant une activite phosphoribosyl transferase |
| EP1180157B1 (en) * | 1999-05-28 | 2012-11-28 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | A combined growth factor-deleted and thymidine kinase-deleted vaccinia virus vector |
| AU2003258168B2 (en) | 2002-08-12 | 2009-10-29 | Sillajen Biotherapeutics, Inc. | Methods and compositions concerning poxviruses and cancer |
| KR101062140B1 (ko) | 2003-07-21 | 2011-09-05 | 트랜스진 에스.에이. | 향상된 시토신 디아미네이즈 활성을 갖는 폴리펩티드 |
| DE602005012535D1 (de) | 2004-11-08 | 2009-03-12 | Transgene Sa | Aus teilen bestehendes kit für die durchführung einer antitumorbehandlung oder antiviralen behandlung in einem säugetier |
| KR20080084528A (ko) * | 2007-03-15 | 2008-09-19 | 제네렉스 바이오테라퓨틱스 인크. | 종양살상형 백시니아 바이러스 암 치료 |
| CA2693623A1 (en) * | 2007-07-18 | 2009-01-22 | Genelux Corporation | Use of a chemotherapeutic agent in the preparation of a medicament for treating or ameliorating an adverse side effect associated with oncolytic viral therapy |
| BRPI0820576B1 (pt) * | 2007-11-19 | 2021-10-19 | Transgène S.A. | Uso de um poxvírus oncolítico compreendendo um gene i4l e/ou f4l defectivo ou uma composição compreendendo o mesmo |
| US20100173013A1 (en) * | 2009-01-08 | 2010-07-08 | Denis Drygin | Treatment of neoplastic disorders using combination therapies |
| CA2709292A1 (en) * | 2009-07-10 | 2011-01-10 | The Governors Of The University Of Alberta | Oncolytic viruses and methods for treating neoplastic disorders |
-
2015
- 2015-04-09 WO PCT/EP2015/057654 patent/WO2015155263A1/en not_active Ceased
- 2015-04-09 KR KR1020167030784A patent/KR102457060B1/ko active Active
- 2015-04-09 EP EP15720276.3A patent/EP3129037B1/en active Active
- 2015-04-09 CN CN201580018763.1A patent/CN106413726B/zh active Active
- 2015-04-09 DK DK15720276.3T patent/DK3129037T3/da active
- 2015-04-09 CA CA2943871A patent/CA2943871C/en active Active
- 2015-04-09 JP JP2016561850A patent/JP6657115B2/ja active Active
- 2015-04-09 AU AU2015243297A patent/AU2015243297B2/en active Active
- 2015-04-09 ES ES15720276T patent/ES2768715T3/es active Active
-
2016
- 2016-08-29 IL IL247535A patent/IL247535B/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015243297B2 (en) | 2020-10-15 |
| CA2943871A1 (en) | 2015-10-15 |
| CA2943871C (en) | 2025-05-06 |
| KR102457060B1 (ko) | 2022-10-19 |
| AU2015243297A1 (en) | 2016-09-29 |
| JP6657115B2 (ja) | 2020-03-04 |
| ES2768715T3 (es) | 2020-06-23 |
| AU2015243297A2 (en) | 2016-09-29 |
| IL247535A0 (en) | 2016-11-30 |
| CN106413726B (zh) | 2020-07-24 |
| WO2015155263A1 (en) | 2015-10-15 |
| JP2017515806A (ja) | 2017-06-15 |
| EP3129037A1 (en) | 2017-02-15 |
| IL247535B (en) | 2019-05-30 |
| CN106413726A (zh) | 2017-02-15 |
| KR20160145058A (ko) | 2016-12-19 |
| EP3129037B1 (en) | 2019-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL282985B (en) | Modified oncolytic viurs | |
| HUE062816T2 (hu) | Onkolitikus vakciniavírus | |
| DK3108000T3 (da) | Adeno-associeret virusvektor | |
| DK3393510T5 (da) | Zikavirusvaccine | |
| HRP20190442T1 (hr) | Kapsid | |
| LT3218504T (lt) | Trijų segmentų arenavirusai kaip vakcinos vektoriai | |
| DK3475433T3 (da) | Adenoviral vektor | |
| EP3374114A4 (en) | WORKBENCH | |
| DK3145949T3 (da) | Lentivirale vektorer | |
| DK3102669T3 (da) | Forbedret bacillevært | |
| EP3303621C0 (en) | SURFACE-BASED TAGMENTATION | |
| DK3234128T3 (da) | Sekventeringskontroller | |
| DK3113795T3 (da) | Rekombinante virale isfahan-vektorer | |
| DK3325631T3 (da) | Rekombinant orf-virusvektor | |
| FR3025617B1 (fr) | Architecture bi-voies | |
| DK3448879T3 (da) | Claudin-6 peptider | |
| DK3375874T3 (da) | Forbedret paramyxovirus-vektor | |
| EP3500280A4 (en) | VIRUS VACCINES | |
| DK3129037T3 (da) | Onkolytiske koppevirusvektorer | |
| EP3624825A4 (en) | RECOMBINANT ONCOLYTIC VIRUS | |
| LT3188755T (lt) | Vakcina | |
| DE102015224551B8 (de) | Klammer | |
| DE112014006555A5 (de) | Kommutierungsschaltung | |
| ES2775740T8 (es) | Péptidos | |
| GB201522317D0 (en) | Chimeric oncolytic virus |